Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Researchers have revealed novel sequence-structure-property relationships for customizing engineered living materials (ELMs), enabling more precise control over their structure and how they respond to ...

At issue as whether Harry came clean to immigration officials about his cocaine, cannabis and psychedelic mushrooms use, as ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...